Articles and use cases on pharmaceutical and medical knowledge management — ontologies, semantic search, AI-ready data, and regulatory intelligence.
Between 60 and 80 percent of clinically valuable information in most healthcare organisations lives in free-text notes, discharge summaries, and narrative reports — completely inaccessible to structured analytics. Natural language processing combined with ontology-grounded extraction is now mature enough to change that at scale.
General-purpose NER models trained on news or Wikipedia text consistently underperform on biomedical documents. This piece explains the specific linguistic characteristics of clinical and pharmaceutical text that require specialised models — and the options for building or adapting them without prohibitive cost.
Identifying entities in biomedical text is only the first step. The real value comes from extracting the relationships between them — drug-indication, drug-contraindication, adverse drug reaction, mechanism of action — and assembling those relationships into a navigable knowledge graph.
Most pharmaceutical organisations have years or decades of valuable clinical and safety data in legacy relational databases that were never designed for semantic querying. Extracting structured knowledge from these systems without disrupting ongoing operations requires a careful read-only integration approach.
The journey from a collection of raw pharmaceutical data sources to a queryable, AI-ready knowledge graph involves five distinct stages, each with its own technical and organisational requirements. This walkthrough maps the full pipeline with the decisions and validation steps that make the difference between a prototype and a production system.
The debate between fully automated knowledge extraction and manual curation is a false dichotomy. The productive question is how to allocate human expert attention where it generates the most value — and design automation to handle everything else reliably.
A knowledge graph is only as valuable as it is current. As source data changes, ontologies are updated, and new evidence emerges, the graph must evolve continuously. Designing for incremental mining from the start is far less costly than retrofitting it later.
Multinational pharmaceutical research generates documents in dozens of languages — clinical summaries in Japanese, adverse event narratives in German, regulatory correspondence in French. Cross-lingual knowledge mining is now feasible at scale, but requires specific design choices that differ from monolingual systems.